LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
X-Ceptor focused on the identification of novel drug candidates that interact with orphan nuclear receptors involved in cholesterol metabolism and cardiovascular disease. Several of its programs were partnered and further developed by large pharmaceutical companies.
Exelixis acquired X-Ceptor in 2004.
X-Ceptor Therapeutics
San Diego, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.